search
Back to results

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1)

Primary Purpose

Obesity

Status
Active
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Cagrilintide
Semaglutide
Placebo cagrilintide
Placebo semaglutide
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female
  • Age above or equal to 18 years at the time of signing informed consent
  • Body mass index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m^2) or b) BMI greater than or equal to 27.0 kg/m^2 with the presence of at least one weight-related comorbidity including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

Exclusion Criteria:

- Glycaemia related: a) Glycated Haemoglobin (HbA1c) greater than or equal to 6.5 percent (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening b) History of type 1 or type 2 diabetes mellitus

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Cagrisema s.c. 2.4 mg/2.4 mg

Cagrilintide s.c. 2.4 mg

Semaglutide s.c. 2.4 mg

Placebo s.c.

Arm Description

Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide once-weekly after a dose escalation period of 16 weeks (0.25 mg of cagrilintide and 0.25 mg of semaglutide from weeks 0-4, 0.5 mg of cagrilintide and 0.5 mg of semaglutide from weeks 5-8, 1 mg of cagrilintide and 1 mg of semaglutide from weeks 9-12 and 1.7 mg of cagrilintide and 1.7 mg of semaglutide from weeks 13-16) during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks.

Participants will receive cagrilintide s.c. 2.4 mg and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks.

Participants will receive semaglutide s.c. 2.4 mg and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks.

Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks.

Outcomes

Primary Outcome Measures

CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight
Measured in percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction
Measured as count of participants

Secondary Outcome Measures

CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of >= 20% weight reduction
Measured as count of participant
CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of >= 25% weight reduction
Measured as count of participant
CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of >= 30% weight reduction
Measured as count of participant
CagriSema 2.4 mg/2.4 mg versus cagrilintide 2.4 mg; and CagriSema 2.4 mg/2.4 mg versus semaglutide 2.4 mg: Relative change in body weight
Measured as percentage (%)
CagriSema 0.5 mg/0.5 mg versus placebo: Relative change in body weight
Measured as percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight
Measured as percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in waist circumference
Measured in centimeters (cm)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in systolic blood pressure (SBP)
Measured in millimeters of mercury (mmHg)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Short Form-36 Version 2.0 (SF-36v2) Physical Functioning Score
Measured as score points. The SF-36v2.0 is a 36-item commonly used generic COA instrument measuring health related quality of life and general health status across disease areas. The SF-36v2.0 for adults with a 1 week recall period (i.e. acute version) measures the individual overall health-related quality of life in 8 health domains (physical functioning, role-physical, bodily pain, general health, social functioning, role-emotional, vitality and mental health). Furthermore, it includes two aggregated scores: a physical component summary score and a mental component summary score.
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Glycated Haemoglobin (HbA1c)
Measured as percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Fasting Plasma Glucose (FPG)
Measured as millimoles per liter (mmol/L)
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in fasting serum insulin
Measured as percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Diastolic Blood Pressure (DBP)
Measured in mmHg
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in total cholesterol
Measured as percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in High-density lipoprotein (HDL) cholesterol
Measured as percentage (%).
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in Low-density lipoprotein (LDL) cholesterol
Measured as percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in Very low-density lipoprotein (VLDL)
Measured as percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in Triglycerides
Measured as percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in Free fatty acids
Measured as percentage (%)
'CagriSema 2.4 mg/2.4 mg versus placebo: Change in total fat mass by Dual energy Xray absorption (DXA) relative to total body mass
Measured in percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in visceral fat mass by DXA
Measured as percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in lean body mass by DXA relative to total body mass
Measured in percentage (%)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in SF-36v2: Physical Component Summary Score and Mental Component Summary Score
Measured as score points. The SF-36v2.0 is a 36-item commonly used generic COA instrument measuring health related quality of life and general health status across disease areas. The SF-36v2.0 for adults with a 1 week recall period (i.e. acute version) measures the individual overall health-related quality of life in 8 health domains (physical functioning, role-physical, bodily pain, general health, social functioning, role-emotional, vitality and mental health). Furthermore, it includes two aggregated scores: a physical component summary score and a mental component summary score.
CagriSema 2.4 mg/2.4 mg versus placebo: Change in IWQOL-Lite-CT Total score
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Number of Treatment Emergent Adverse Events (TEAEs)
Measured as count of events
Number of Treatment Emergent Serious adverse events (TESAEs)
Measured as count of events.

Full Information

First Posted
October 3, 2022
Last Updated
June 30, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT05567796
Brief Title
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Acronym
REDEFINE 1
Official Title
Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 1, 2022 (Actual)
Primary Completion Date
January 19, 2025 (Anticipated)
Study Completion Date
October 19, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
3400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cagrisema s.c. 2.4 mg/2.4 mg
Arm Type
Experimental
Arm Description
Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide once-weekly after a dose escalation period of 16 weeks (0.25 mg of cagrilintide and 0.25 mg of semaglutide from weeks 0-4, 0.5 mg of cagrilintide and 0.5 mg of semaglutide from weeks 5-8, 1 mg of cagrilintide and 1 mg of semaglutide from weeks 9-12 and 1.7 mg of cagrilintide and 1.7 mg of semaglutide from weeks 13-16) during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks.
Arm Title
Cagrilintide s.c. 2.4 mg
Arm Type
Active Comparator
Arm Description
Participants will receive cagrilintide s.c. 2.4 mg and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks.
Arm Title
Semaglutide s.c. 2.4 mg
Arm Type
Active Comparator
Arm Description
Participants will receive semaglutide s.c. 2.4 mg and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks.
Arm Title
Placebo s.c.
Arm Type
Placebo Comparator
Arm Description
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks.
Intervention Type
Drug
Intervention Name(s)
Cagrilintide
Intervention Description
Cagrilintide will be administered subcutaneously.
Intervention Type
Drug
Intervention Name(s)
Semaglutide
Intervention Description
Participants will recieve semaglutide subcutaneously.
Intervention Type
Drug
Intervention Name(s)
Placebo cagrilintide
Intervention Description
Participants will receive placebo matched to cagrilintide.
Intervention Type
Drug
Intervention Name(s)
Placebo semaglutide
Intervention Description
Participants will receive placebo matched to semaglutide.
Primary Outcome Measure Information:
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight
Description
Measured in percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction
Description
Measured as count of participants
Time Frame
From baseline (week 0) to end of treatment (week 68)
Secondary Outcome Measure Information:
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of >= 20% weight reduction
Description
Measured as count of participant
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of >= 25% weight reduction
Description
Measured as count of participant
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of >= 30% weight reduction
Description
Measured as count of participant
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus cagrilintide 2.4 mg; and CagriSema 2.4 mg/2.4 mg versus semaglutide 2.4 mg: Relative change in body weight
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 0.5 mg/0.5 mg versus placebo: Relative change in body weight
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to week 8
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to week 20
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in waist circumference
Description
Measured in centimeters (cm)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in systolic blood pressure (SBP)
Description
Measured in millimeters of mercury (mmHg)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score
Description
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Short Form-36 Version 2.0 (SF-36v2) Physical Functioning Score
Description
Measured as score points. The SF-36v2.0 is a 36-item commonly used generic COA instrument measuring health related quality of life and general health status across disease areas. The SF-36v2.0 for adults with a 1 week recall period (i.e. acute version) measures the individual overall health-related quality of life in 8 health domains (physical functioning, role-physical, bodily pain, general health, social functioning, role-emotional, vitality and mental health). Furthermore, it includes two aggregated scores: a physical component summary score and a mental component summary score.
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Glycated Haemoglobin (HbA1c)
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Fasting Plasma Glucose (FPG)
Description
Measured as millimoles per liter (mmol/L)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in fasting serum insulin
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Diastolic Blood Pressure (DBP)
Description
Measured in mmHg
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in total cholesterol
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in High-density lipoprotein (HDL) cholesterol
Description
Measured as percentage (%).
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in Low-density lipoprotein (LDL) cholesterol
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in Very low-density lipoprotein (VLDL)
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in Triglycerides
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in Free fatty acids
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
'CagriSema 2.4 mg/2.4 mg versus placebo: Change in total fat mass by Dual energy Xray absorption (DXA) relative to total body mass
Description
Measured in percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in visceral fat mass by DXA
Description
Measured as percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in lean body mass by DXA relative to total body mass
Description
Measured in percentage (%)
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in SF-36v2: Physical Component Summary Score and Mental Component Summary Score
Description
Measured as score points. The SF-36v2.0 is a 36-item commonly used generic COA instrument measuring health related quality of life and general health status across disease areas. The SF-36v2.0 for adults with a 1 week recall period (i.e. acute version) measures the individual overall health-related quality of life in 8 health domains (physical functioning, role-physical, bodily pain, general health, social functioning, role-emotional, vitality and mental health). Furthermore, it includes two aggregated scores: a physical component summary score and a mental component summary score.
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
CagriSema 2.4 mg/2.4 mg versus placebo: Change in IWQOL-Lite-CT Total score
Description
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Time Frame
From baseline (week 0) to end of treatment (week 68)
Title
Number of Treatment Emergent Adverse Events (TEAEs)
Description
Measured as count of events
Time Frame
From baseline (week 0) to end of study-main part (week 75)
Title
Number of Treatment Emergent Serious adverse events (TESAEs)
Description
Measured as count of events.
Time Frame
From baseline (week 0) to end of study-main part (week 75)

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female Age above or equal to 18 years at the time of signing informed consent Body mass index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m^2) or b) BMI greater than or equal to 27.0 kg/m^2 with the presence of at least one weight-related comorbidity including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease Exclusion Criteria: - Glycaemia related: a) Glycated Haemoglobin (HbA1c) greater than or equal to 6.5 percent (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening b) History of type 1 or type 2 diabetes mellitus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Reporting Office dept. 2834
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Golden
State/Province
Colorado
ZIP/Postal Code
80401
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Fleming Island
State/Province
Florida
ZIP/Postal Code
32003
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32801
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32825
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33027
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Plantation
State/Province
Florida
ZIP/Postal Code
33324
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Conyers
State/Province
Georgia
ZIP/Postal Code
30094
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96814
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60640
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Skokie
State/Province
Illinois
ZIP/Postal Code
60077
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46260
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Buckley
State/Province
Michigan
ZIP/Postal Code
49620
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Saint Peters
State/Province
Missouri
ZIP/Postal Code
63303
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Vestal
State/Province
New York
ZIP/Postal Code
13850
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27517
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27405
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27408
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27609
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Wadsworth
State/Province
Ohio
ZIP/Postal Code
44281
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Norman
State/Province
Oklahoma
ZIP/Postal Code
73072
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104-3317
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Cumberland
State/Province
Rhode Island
ZIP/Postal Code
02864
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
North Charleston
State/Province
South Carolina
ZIP/Postal Code
29405
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Simpsonville
State/Province
South Carolina
ZIP/Postal Code
29681-1538
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Bristol
State/Province
Tennessee
ZIP/Postal Code
37620
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75226
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-9302
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Longview
State/Province
Texas
ZIP/Postal Code
75605
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Arlington
State/Province
Virginia
ZIP/Postal Code
22206
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Newport News
State/Province
Virginia
ZIP/Postal Code
23606
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Winchester
State/Province
Virginia
ZIP/Postal Code
22601-3834
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Olympia
State/Province
Washington
ZIP/Postal Code
98502
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Renton
State/Province
Washington
ZIP/Postal Code
98057
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Caba
ZIP/Postal Code
C1060ABA
Country
Argentina
Facility Name
Novo Nordisk Investigational Site
City
Caba
ZIP/Postal Code
C1120AAC
Country
Argentina
Facility Name
Novo Nordisk Investigational Site
City
Ciudad de Buenos Aires
ZIP/Postal Code
C1204AAD
Country
Argentina
Facility Name
Novo Nordisk Investigational Site
City
Santa Rosa
ZIP/Postal Code
6300
Country
Argentina
Facility Name
Novo Nordisk Investigational Site
City
Santiago del Estero
ZIP/Postal Code
G4200
Country
Argentina
Facility Name
Novo Nordisk Investigational Site
City
Brookvale
State/Province
New South Wales
ZIP/Postal Code
2100
Country
Australia
Facility Name
Novo Nordisk Investigational Site
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Facility Name
Novo Nordisk Investigational Site
City
Kotara
State/Province
New South Wales
ZIP/Postal Code
2289
Country
Australia
Facility Name
Novo Nordisk Investigational Site
City
Taringa
State/Province
Queensland
ZIP/Postal Code
4608
Country
Australia
Facility Name
Novo Nordisk Investigational Site
City
Bonheiden
ZIP/Postal Code
2820
Country
Belgium
Facility Name
Novo Nordisk Investigational Site
City
Boussu
ZIP/Postal Code
7300
Country
Belgium
Facility Name
Novo Nordisk Investigational Site
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Novo Nordisk Investigational Site
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Facility Name
Novo Nordisk Investigational Site
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Novo Nordisk Investigational Site
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Novo Nordisk Investigational Site
City
Dupnitsa
State/Province
Kyustendil
ZIP/Postal Code
2600
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Blagoevgrad
ZIP/Postal Code
2700
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Montana
ZIP/Postal Code
3400
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Pleven
ZIP/Postal Code
5800
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Plovdiv
ZIP/Postal Code
4006
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Ruse
ZIP/Postal Code
7002
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Smolyan
ZIP/Postal Code
4700
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Sofia
ZIP/Postal Code
1517
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Sofia
ZIP/Postal Code
1527
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Sofia
ZIP/Postal Code
1618
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Varna
ZIP/Postal Code
9020
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Yambol
ZIP/Postal Code
8600
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6H 2L4
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Sherwood Park
State/Province
Alberta
ZIP/Postal Code
T8H 0N2
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3Z 2N6
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Victoria
State/Province
British Columbia
ZIP/Postal Code
V8V 4A1
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Moncton
State/Province
New Brunswick
ZIP/Postal Code
E1G 1A7
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 1V7
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8M 1K7
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Aarhus N
ZIP/Postal Code
8200
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Hellerup
ZIP/Postal Code
2900
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Køge
ZIP/Postal Code
4600
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Helsinki
ZIP/Postal Code
00290
Country
Finland
Facility Name
Novo Nordisk Investigational Site
City
Kuopio
ZIP/Postal Code
70210
Country
Finland
Facility Name
Novo Nordisk Investigational Site
City
Oulu
ZIP/Postal Code
90220
Country
Finland
Facility Name
Novo Nordisk Investigational Site
City
Turku
ZIP/Postal Code
20520
Country
Finland
Facility Name
Novo Nordisk Investigational Site
City
Paris Cedex 13
ZIP/Postal Code
75651
Country
France
Facility Name
Novo Nordisk Investigational Site
City
Pierre Benite
ZIP/Postal Code
69310
Country
France
Facility Name
Novo Nordisk Investigational Site
City
Saint Herblain
ZIP/Postal Code
44800
Country
France
Facility Name
Novo Nordisk Investigational Site
City
Strasbourg
ZIP/Postal Code
67098
Country
France
Facility Name
Novo Nordisk Investigational Site
City
Venissieux
ZIP/Postal Code
69200
Country
France
Facility Name
Novo Nordisk Investigational Site
City
Bad Mergentheim
ZIP/Postal Code
97980
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Elsterwerda
ZIP/Postal Code
04910
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Essen
ZIP/Postal Code
45136
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Hamburg
ZIP/Postal Code
22607
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Leipzig
ZIP/Postal Code
04107
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Münster
ZIP/Postal Code
48145
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Stuttgart
ZIP/Postal Code
70378
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Wangen
ZIP/Postal Code
88239
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Surat
State/Province
Gujarat
ZIP/Postal Code
395002
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Belgaum
State/Province
Karnataka
ZIP/Postal Code
590001
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Kozhikode
State/Province
Kerala
ZIP/Postal Code
673008
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400004
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400011
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
440003
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411001
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411004
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411021
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Delhi
State/Province
New Delhi
ZIP/Postal Code
110002
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Chandigarh
State/Province
Punjab
ZIP/Postal Code
160012
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302004
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302017
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Vellore
State/Province
Tamil Nadu
ZIP/Postal Code
632004
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Hyderabad
State/Province
Telangana
ZIP/Postal Code
500032
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Delhi
ZIP/Postal Code
110029
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Hyderabad
ZIP/Postal Code
500012
Country
India
Facility Name
Novo Nordisk Investigational Site
City
Bari
State/Province
BA
ZIP/Postal Code
70124
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Roma
State/Province
RM
ZIP/Postal Code
00128
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Siena
State/Province
SI
ZIP/Postal Code
53100
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Arezzo
ZIP/Postal Code
52100
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Catania
ZIP/Postal Code
95122
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Catanzaro
ZIP/Postal Code
88100
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Partinico
ZIP/Postal Code
90047
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Roma
ZIP/Postal Code
00133
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Roma
ZIP/Postal Code
00161
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Aichi
ZIP/Postal Code
468-0009
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Chiba-shi, Chiba
ZIP/Postal Code
260-8677
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Gunma
ZIP/Postal Code
373-0036
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kanagawa
ZIP/Postal Code
231-0023
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Osaka
ZIP/Postal Code
530-0001
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Saitama
ZIP/Postal Code
350-0851
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Sapporo City, Hokkaido
ZIP/Postal Code
004-0004
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Sendai-shi, Miyagi
ZIP/Postal Code
983-0039
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Suita-shi, Osaka
ZIP/Postal Code
565-0853
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
103-0027
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
104-0031
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
141-0032
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
160-0008
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
169-0072
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Bucheon-si
State/Province
Gyeonggi-do
ZIP/Postal Code
14647
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Daegu
ZIP/Postal Code
14233
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Daejeon
ZIP/Postal Code
35233
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Incheon
ZIP/Postal Code
21565
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Seongnam-si, Gyeonggi-do
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Yangsan
ZIP/Postal Code
50612
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44650
Country
Mexico
Facility Name
Novo Nordisk Investigational Site
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44670
Country
Mexico
Facility Name
Novo Nordisk Investigational Site
City
Monterrey
State/Province
Nuevo Leon
ZIP/Postal Code
64060
Country
Mexico
Facility Name
Novo Nordisk Investigational Site
City
Monterrey
State/Province
Nuevo León
ZIP/Postal Code
64020
Country
Mexico
Facility Name
Novo Nordisk Investigational Site
City
Aguascalientes
ZIP/Postal Code
20230
Country
Mexico
Facility Name
Novo Nordisk Investigational Site
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands
Facility Name
Novo Nordisk Investigational Site
City
Arnhem
ZIP/Postal Code
6815 AD
Country
Netherlands
Facility Name
Novo Nordisk Investigational Site
City
Hoofddorp
ZIP/Postal Code
2134 TM
Country
Netherlands
Facility Name
Novo Nordisk Investigational Site
City
Roosendaal
ZIP/Postal Code
4708 AE
Country
Netherlands
Facility Name
Novo Nordisk Investigational Site
City
Zwijndrecht
ZIP/Postal Code
3331 LZ
Country
Netherlands
Facility Name
Novo Nordisk Investigational Site
City
Legnica
State/Province
Dolnośląskie
ZIP/Postal Code
59-220
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Bydgoszcz
State/Province
Kujawsko-Pomorskie Voivodeship
ZIP/Postal Code
85-094
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Bygdoszcz
State/Province
Kuyavian-Pomeranian Voivodeship
ZIP/Postal Code
85-796
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Lublin
State/Province
Lubelskie Voivodeship
ZIP/Postal Code
20-333
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Warszawa
State/Province
Mazovian Voivodeship
ZIP/Postal Code
02-117
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
00-416
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Krakow
State/Province
Małopolskie
ZIP/Postal Code
30-363
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Bialystok
State/Province
Podlaskie Voivodeship
ZIP/Postal Code
15-276
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Bialystok
State/Province
Podlaskie Voivodeship
ZIP/Postal Code
15-281
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Bialystok
State/Province
Podlaskie Voivodeship
ZIP/Postal Code
15-879
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Gdansk
State/Province
Pomorskie
ZIP/Postal Code
80-952
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Katowice
State/Province
Slaskie Voivodeship
ZIP/Postal Code
40-772
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Elblag
State/Province
Warmińsko-Mazurskie
ZIP/Postal Code
82-300
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Poznan
State/Province
Wielkopolskie Voivodeship
ZIP/Postal Code
60-589
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Poznań
State/Province
Wielkopolskie Voivodeship
ZIP/Postal Code
60-198
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Legnica
ZIP/Postal Code
59-220
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Warszawa
ZIP/Postal Code
00-416
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Novo Nordisk Investigational Site
City
Belgrade
ZIP/Postal Code
11080
Country
Serbia
Facility Name
Novo Nordisk Investigational Site
City
Novi Sad
ZIP/Postal Code
21000
Country
Serbia
Facility Name
Novo Nordisk Investigational Site
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1501
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1812
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Lenasia
State/Province
Gauteng
ZIP/Postal Code
1827
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Midrand
State/Province
Gauteng
ZIP/Postal Code
1685
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0184
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Durban
State/Province
KwaZulu-Natal
ZIP/Postal Code
4091
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Durban
State/Province
KwaZulu-Natal
ZIP/Postal Code
4450
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Brits
State/Province
North West
ZIP/Postal Code
0250
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7708
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
Castilleja Dela Cuesta Sevilla
ZIP/Postal Code
41950
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
León
ZIP/Postal Code
24071
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
Sevilla
ZIP/Postal Code
41003
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
Sevilla
ZIP/Postal Code
41010
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
Facility Name
Novo Nordisk Investigational Site
City
Taipei City
ZIP/Postal Code
10048
Country
Taiwan
Facility Name
Novo Nordisk Investigational Site
City
Ankara
State/Province
Cankaya
ZIP/Postal Code
06800
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Adana
ZIP/Postal Code
01000
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Adana
ZIP/Postal Code
01250
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Ankara
ZIP/Postal Code
06800
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Antalya
ZIP/Postal Code
07058
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Hatay
ZIP/Postal Code
31060
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Istanbul
ZIP/Postal Code
34130
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Istanbul
ZIP/Postal Code
34390
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Istanbul
ZIP/Postal Code
34400
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Istanbul
ZIP/Postal Code
34668
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Istanbul
ZIP/Postal Code
34722
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Sivas
ZIP/Postal Code
58140
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Blackpool
ZIP/Postal Code
FY3 7EN
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
Bristol
ZIP/Postal Code
BS10 5NB
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
Chester
ZIP/Postal Code
CH2 1UL
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
Chippenham
ZIP/Postal Code
SN14 6GT
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
Coventry
ZIP/Postal Code
CV2 2DX
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
Liverpool
ZIP/Postal Code
L9 7AL
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
London
ZIP/Postal Code
W12 0HS
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
London
ZIP/Postal Code
WC1E 6JF
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
Orpington
ZIP/Postal Code
BR6 8ND
Country
United Kingdom
Facility Name
Novo Nordisk Investigational Site
City
Taunton
ZIP/Postal Code
TA1 5DA
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

We'll reach out to this number within 24 hrs